Recently, the new hybrid chelator DATA (6-amino-1,4-diazepine-triacetate) has been introduced, which has the advantage of high yield and radiolabelling of DATA-based octreotide derivative (TOC) at room temperature in contrast to tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA) that needs 95 °C for effective labelling. However, the diagnostic potential of DATA-TOC has not been studied with other chelators in humans. The aim of this study was to compare the diagnostic efficacy of [⁶⁸Ga]Ga-DATA-TOC with [⁶⁸Ga]Ga-DOTA-NOC (which is the current standard for imaging neuroendocrine tumours (NET)) in patients of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

中文翻译：

---

评价[68Ga] Ga-DATA-TOC对神经内分泌肿瘤的成像：与[68Ga] Ga-DOTA-NOC PET / CT进行比较。

最近，引入了新的杂化螯合剂DATA（6-氨基-1,4-二氮杂三乙酸三酯），与四氮杂环十二烷-相比，具有基于DATA的奥曲肽衍生物（TOC）的高收率和放射性标记的优点。 1,95,1,4,7,10-四乙酸（DOTA）需要有效的标记。但是，尚未与其他螯合剂一起研究DATA-TOC的诊断潜力。这项研究的目的是比较[ ⁶⁸ Ga] Ga-DATA-TOC与[ ⁶⁸ Ga] Ga-DOTA-NOC（这是目前对神经内分泌肿瘤（NET）成像的标准）在胃肠道胰腺神经内分泌患者中的诊断功效肿瘤（GEP-NET）。